Our Treatment Areas

The Therapeutics Division in Canada is comprised of 3 distinct businesses dedicated to improving the lives of Canadians in the following diseases:

Lysosomal Storage Disease (LSD’s)

LSD’s are a group of rare genetic diseases that affect the lives of hundreds of Canadians. The treatments developed by Genzyme; Enzyme Replacement Therapy (ERT) allows people affected with these diseases to have significant improvement in the quality and longevity of their lives. This would not be possible without the advent of ERT treatments.

Renal Disease

End Stage Renal Disease (ESRD) affects tens of thousands of Canadians. As kidney function fails, dialysis is often the only option available to these people. Once on dialysis, there is a need to replicate the function of the kidney. In 90% of dialysis patients, binding phosphate from protein in a patient’s diet is a required treatment.

Cancer

Over 2000 Canadian will be diagnosed with well-differentiated Thyroid cancer this year. The diagnosis will bring numerous visits to physicians and hospitals, a surgical procedure to remove the cancerous thyroid (thyroidectomy), and a lifetime of thyroid hormone suppression drugs to reduce the risk of recurrence of the cancer. A yearly test, requiring 4-6 weeks off their standard medication, leaving people with thyroid cancer to suffering drug withdrawal that results in significant morbidity and reduction in their quality of life.

Patients with Thyroid Cancer now have an alternative to drug withdrawal. Thyroid Stimulating Hormone (TSH) allows patients to undergo their annual testing by elevating TSH levels in their blood.

Biosurgery

The Biosurgery Division in Canada markets and distributes biotechnology products for the surgical arena. Our focus is in two medical areas – Osteoarthritis Therapy and Adhesion Prevention.

Within these areas our portfolio includes a range of marketed biotherapeutics, biomaterials and medical devices with many more in development.

Osteoarthritis Therapy

Osteoarthritis(OA) is a disease that can cause pain and stiffness in the joints due to the deterioration of both the joint cartilage and synovial fluid.

Synvisc® (Hylan G-F 20)for injection is a natural substance proven to reduce pain and enhance mobility.

Adhesion Prevention

Adhesions are fibrous bands that connect tissue surfaces. They are a consequence of surgery as the body heals and can cause significant complications for the patient.

Seprafilm®, CV Seprafilm™, and Sepramesh™ are biomaterials designed to reduce the occurrence of post surgical adhesions.

Privacy Policy - Canada USA | Terms and Conditions of Use | | © 2003-2010 Genzyme Corporation. All rights reserved.